The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 3 Comments »
Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate risk, low risk, radiation, SBRT, stereotactic | 1 Comment »
Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adenocarcinoma, damage, DNA, ductal, homologous, mismatch, prostate, repair, sequencing | Leave a comment »
So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 5 Comments »
